AndreaBozzo/ceres-open-data-index huggingface dataset:
Plan Attributes PUF - PY2020

The Plan Attributes PUF (Plan-PUF) is one of the files that make up the Marketplace PUF. The Plan-PUF contains plan-level data on maximum out of pocket payments, deductibles, cost sharing, health savings account (HSA) eligibility, formulary ID, and other plan attributes. These data either originate from the Plans &amp; Benefits template (i.e., template field), an Excel based form used by issuers to describe their plans in the QHP/SADP application process, or were generated by CCIIO for use in data processing (i.e., system-generated). The issuer can also import data created in other templates (e.g., Network IDs from the Network ID template, Service Area IDs from the Service Area template, and Formulary IDs from the Prescription Drug template) to use as allowable values for the applicable fields in the Plans &amp; Benefits template, or enter these values manually.
Death rates for suicide, by sex, race, Hispanic origin, and age: United States

Data on death rates for suicide, by selected population characteristics. Please refer to the PDF or Excel version of this table in the HUS 2019 Data Finder (https://www.cdc.gov/nchs/hus/contents2019.htm) for critical information about measures, definitions, and changes over time. 

SOURCE: NCHS, National  Vital Statistics System (NVSS); Grove RD, Hetzel AM. Vital statistics rates in the United States, 1940–1960. National Center for Health Statistics. 1968; numerator data from NVSS annual public-use Mortality Files; denominator data from U.S. Census Bureau national population estimates; and Murphy SL, Xu JQ, Kochanek KD, Arias E, Tejada-Vera B. Deaths: Final data for 2018. National Vital Statistics Reports; vol 69 no 13. Hyattsville, MD: National Center for Health Statistics. 2021. Available from: https://www.cdc.gov/nchs/products/nvsr.htm. For more information on the National Vital Statistics System, see the corresponding Appendix entry at https://www.cdc.gov/nchs/data/hus/hus19-appendix-508.pdf.
Table 20. Dependence or Abuse of Illicit Drugs or Alcohol in the Past Year, by Age Group and State: Percentages, Annual Averages Based on 2013 and 2014 NSDUHs

Table 20. Dependence or Abuse of Illicit Drugs or Alcohol in the Past Year, by Age Group and State: Percentages, Annual Averages Based on 2013 and 2014 NSDUHs
Patent AT-E400089-T1: [Translated] SISO DECODER WITH SUBBLOCK PROCESSING AND SUBBLOCK BASED STOP CRITERION

The present invention relates to SISO decoder for iteratively decoding a block of received information symbols (r), in particular for use in a turbo decoder, said block being divided into a number of windows of information symbols. In order to achieve a significant reduction of power consumption a SISO decoder is proposed comprising at least one SISO decoding unit (17, 21) for SISO decoding of the received information symbols (r) of a window, wherein a stopping criterion is applied to each window. This allows to abort iterative decoding for each window individually once convergence of decoding is determined by marking a window or sub-block inactive (17,23). An inactive window is no longer SISO decoded in subsequent iterations.
Patent AT-E399985-T1: [Translated] METHOD FOR DETERMINING THE PROPORTION OF A GAS COMPONENT IN A GAS MIXTURE

An asynchronous motor is used as the recirculation drive. Its slip, i.e. the deficit below synchronous speed, is measured. This is a measure of the proportion of the gas component of interest, e.g. steam, under given conditions of pressure and temperature of the gas mixture. Preferred Features: The measured slip is used to control the composition of the gas mixture, especially for moisture control of the medium recirculated in equipment treating foods.
Genetic epidemiology: Giant cell arteritis and polymyalgia rheumatica

Giant cell arteritis (GCA) (temporal arteritis) and polymyalgia rheumatica (PMR) are common, frequently related conditions in people generally over 50 years of age. Most studies have shown an association of GCA with HLA-DRB1*04 alleles. As regards isolated PMR, however, the HLA class II genetic susceptibility varies from one population to another. Besides associations with HLA, tumor necrosis factor appears to influence susceptibility to both conditions. Genetic polymorphisms have also been considered to be important candidates as factors of susceptibility to GCA and PMR. In this regard, gene polymorphisms for ICAM-1 (intercellular adhesion molecule 1), RANTES (regulated upon activation, normal T cell expressed, and presumably secreted), and interleukin (IL)-1 receptor antagonist seem to play a role in the pathogenesis of GCA and PMR in some populations. However, additional studies are required to clarify the genetic influence on susceptibility to these conditions.
Expense and benefit of neoadjuvant treatment in squamous cell carcinoma of the esophagus

Background
          The effectiveness of neoadjuvant treatment (NT) prior to resection of squamous cell carcinoma of the esophagus (SCCE) in terms of prolonged survival has not been proven by randomized trials. Facing considerable financial expenses and with concerns regarding the consumption of the patient's remaining survival time, this study aims to provide rationales for pretreating resection candidates.
        
        
          Methods
          From March 1986 to March 1999, patients undergoing resection for SCCE were documented prospectively. Since 1989, NT was offered to patients with mainly upper and middle third T3 or T4 tumors or T2 N1 stage who were fit for esophagectomy. Until 1993, NT consisted of chemotherapy. Since that time chemoradiation has also been applied. The parameters for expense and benefit of NT are costs, pretreatment time required, postoperative morbidity and mortality, clinical and histopathological response, and actuarial survival.
        
        
          Results
          Two hundred and three patients were treated, 170 by surgery alone and 33 by NT + surgery. Postoperative morbidity and mortality were 52% to 30% and 12% to 6%, respectively (p = n.s.). The response to NT was detected in 23 patients (70%). In 11 instances (33%), the primary tumor lesion was histopathologically eradicated. Survival following NT + surgery was significantly prolonged in node-positive patients with a median survival of 12 months to 19 months (p = 0.0193). The average pretreatment time was 113 ± 43 days, and reimbursement for NT to the hospital amounted to Euro 9.834.
        
        
          Conclusions
          NT did not increase morbidity and mortality. Expenses for pretreatment, particularly time and costs, are considerable. However, taking into account that the results are derived from a non-randomized study, patients with regionally advanced tumor stages seem to benefit, as seen by their prolonged survival.
Compound 530508: 3-Cyclopentylpropionic acid, heptadecyl ester

Chemical compound data from PubChem database. IUPAC Name: heptadecyl 3-cyclopentylpropanoate. Molecular Formula: C25H48O2. Molecular Weight: 380.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
PR-81-01

This Program Regulation (PR) clarifies the circumstances under which Federal Financial participation (FFP) is available to States in otherwise allowable State expenditures in the programs established under titles I, IV-A, IV-B, IV-D, IV- E, X, XIV, XVI(AABD), XIX, and XX of the Social Security Act, i.e. financial assistance, child welfare, child support enforcement, adoption assistance, and social services programs and the Medicaid program. FFP is currently available with respect to otherwise allowable State expenditures *46135 for these programs made before September 30, 1978 only if the State filed a claim for FFP within one year of the expenditure.

Metadata-only record linking to the original dataset. Open original dataset below.
Weekly Provisional Counts of Deaths by State and Select Causes, 2020-2023

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov.

Provisional counts of deaths by the week the deaths occurred, by state of occurrence, and by select underlying causes of death for 2020-2023.  The dataset also includes weekly provisional counts of death for COVID-19, coded to ICD-10 code U07.1 as an underlying or multiple cause of death.

NOTE: death counts are presented with a one week lag.
Patent AT-E399978-T1: [Translated] ANGLE MEASURING DEVICE

The device has a measuring tape (4) attached by clamping to a concave surface (3) of a carrier body (1). The extent of the concave surface is defined by detent surfaces (6,7) on each end of the measuring tape. At least one of the detent surfaces is adjustable using an adjusting device (9), so that the spacing of the detent surfaces can be matched to the length of the measuring tape.
NNDSS - Table II. Hepatitis (viral, acute)

NNDSS - Table II. Hepatitis (viral, acute) - 2015.In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed.The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data.  Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable.    -: No reported cases.    N: Not reportable.    NN: Not Nationally Notifiable.    NP: Nationally notifiable but not published.    Cum: Cumulative year-to-date counts.    Med: Median.    Max: Maximum. * Three low incidence conditions, rubella, rubella congenital, and tetanus, have been moved to Table 2 to facilitate case count verification with reporting jurisdictions. ��� Case counts for reporting year 2015 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly.
Hospital Inpatient Discharges (SPARCS De-Identified): Inpatient Quality Indicators (IQI) by Hospital: Beginning 2009

The datasets contain hospital discharges counts (numerators, denominators, volume counts), observed, expected and risk-adjusted rates with corresponding 95% confidence intervals for IQIs generated using methodology developed by Agency for Healthcare Research and Quality (AHRQ).
The IQIs are a set of measures that provide a perspective on hospital quality of care using hospital administrative data. These indicators reflect quality of care inside hospitals and include inpatient mortality for certain procedures and medical conditions; utilization of procedures for which there are questions of overuse, underuse, and misuse; and volume of procedures for which there is some evidence that a higher volume of procedures is associated with lower mortality.
All the IQI measures were calculated using Statewide Planning and Research Cooperative System (SPARCS) inpatient data beginning 2009. US Census data files provided by AHRQ were used to derive denominators for county level (area level) IQI measures.

The mortality, volume and utilization measures IQIs are presented by hospital as rates or counts. Area-level utilization measures are presented by county as rates.
Genetically modified parthenocarpic eggplants: improved fruit productivity under both greenhouse and open field cultivation.

Background
          Parthenocarpy, or fruit development in the absence of fertilization, has been genetically engineered in eggplant and in other horticultural species by using the DefH9-iaaM gene. The iaaM gene codes for tryptophan monoxygenase and confers auxin synthesis, while the DefH9 controlling regions drive expression of the  gene specifically in the ovules and placenta. A previous greenhouse trial for winter production of genetically engineered (GM) parthenocarpic eggplants demonstrated a significant increase (an average of 33% increase) in fruit production concomitant with a reduction in cultivation costs.
        
        
          Results
          GM parthenocarpic eggplants have been evaluated in three field trials. Two greenhouse spring trials have shown that these plants outyielded the corresponding untransformed genotypes, while a summer trial has shown that improved fruit productivity in GM eggplants can also be achieved in open field cultivation. Since the fruits were always seedless, the quality of GM eggplant fruits was improved as well. RT-PCR analysis demonstrated that the DefH9-iaaM gene is expressed during late stages of fruit development.
        
        
          Conclusions
          The DefH9-iaaM parthenocarpic gene is a biotechnological tool that enhances the agronomic value of all eggplant genotypes tested. The main advantages of DefH9-iaaM eggplants are: i) improved fruit productivity (at least 30–35%) under both greenhouse and open field cultivation; ii) production of good quality (marketable) fruits during different types of cultivation; iii) seedless fruit with improved quality. Such advantages have been achieved without the use of either male or female sterility genes.
Debate: Are surrogate end-point studies worth the effort?

Surrogate end-points of cardiovascular disease can provide useful information in cross-sectional, prospective and interventional studies. They provide information on association with risk factors, natural history and factors associated with disease progression. Because every participant can reach an end-point, sufficient power can be attained with much smaller numbers of subjects in surrogate end-point studies than in studies that use clinical endpoints, so that the costs are likely to be substantially less. Measures of carotid intima-media thickness (IMT) by B-mode ultrasonography and of coronary calcification by electron beam computed tomography (EBCT) appear to be the most promising surrogate end-points.
Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients

Background
          Fabry disease (FD, OMIM 301500) is an X-linked inborn error of glycosphingolipid metabolism due to the deficient activity of alpha-galactosidase A, a lysosomal enzyme. While the progressive systemic deposition of uncleaved glycosphingolipids throughout the body is known to have protean clinical manifestations, few data are available regarding the cochlear involvement.
        
        
          Methods
          We non-invasively investigated cochlear functions in 22 consecutive hemizygous males (age 19–64 years, mean 39) affected with classic FD. Conventional audiometry, tympanometry, ABR audiometry, otoacoustic emissions were performed in all patients, together with medical history record and physical examination as part of an exhaustive baseline evaluation prior to enzyme replacement therapy.
        
        
          Results
          A total of 12 patients (54.5%) with classic FD were found to have abnormal audition. Five patients had progressive hearing loss and seven patients (32%) experienced sudden deafness. In addition, a hearing loss on high-tone frequencies was found in 7 out of the 10 remaining patients without clinical impairment, despite their young age at time of examination. The incidence of hearing loss appeared significantly increased in FD patients with kidney failure (P < 0.01) or cerebrovascular lesions (P < 0.01), whereas there was no correlation with left ventricular hypertrophy. In addition, tinnitus aurium was also found in six patients (27%).
        
        
          Conclusion
          This is the first evidence of a high incidence of both progressive hearing loss and sudden deafness in a cohort of male patients affected with classic Fabry disease. The exact pathophysiologic mechanism(s) of the cochlear involvement deserves further studies.
Compound 526481: N-tert-butyl-2,2,3,3,4,4,4-heptafluoro-N-[2-trimethylsilyloxy-3-[(5-trimethylsilyloxy-5,6,7,8-tetrahydronaphthalen-1-yl)oxy]propyl]butanamide

Chemical compound data from PubChem database. IUPAC Name: N-tert-butyl-2,2,3,3,4,4,4-heptafluoro-N-[2-trimethylsilyloxy-3-[(5-trimethylsilyloxy-5,6,7,8-tetrahydronaphthalen-1-yl)oxy]propyl]butanamide. Molecular Formula: C27H42F7NO4Si2. Molecular Weight: 633.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399580-T1: [Translated] METHOD FOR DYEING AND PERMANENTLY SHAPING HAIR

Process to simultaneously color and permanently restructure hair, wherein  (a) an oxidative hair colorant is applied to the hair based on at least one developer substance and least one coupler substance,  (b) the oxidative hair colorant is left on for 5 to 60 minutes,  (c) the oxidative hair colorant is rinsed out of the hair,  (d) an acidic intermediate treatment agent with a pH of from 2 to 6 is applied to the hair,  (e) after an action period of from 1 to 10 minutes, the intermediate treatment agent is rinsed out, if necessary, and the hair is then rolled up onto curlers,  (f) a keratin-reducing permanent restructuring agent is applied to the hair,  (g) after an action period of from 1 to 30 minutes, the keratin-reducing agent is rinsed out, if necessary,  (h) the hair is fixed with an oxidative material,  (i) after an action period of from 3 to 15 minutes, the hair is rinsed with water, if necessary and then treated with an acidic rinse.    The process is intended to enable better, faster, and gentler coloring of human hair, particularly natural hair, than was previously possible, as well as to maintain the color intensity of colored hair or to refresh (renew) it, and to improve the hair shine while simultaneously restructuring the hair.
Compound 529927: Nilvadipine M (dehydro-desisopropyl, methyl ester)

Chemical compound data from PubChem database. IUPAC Name: dimethyl 2-cyano-6-methyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate. Molecular Formula: C17H13N3O6. Molecular Weight: 355.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Phylogenetic analysis of methanogens from the bovine rumen

Background
          Interest in methanogens from ruminants has resulted from the role of methane in global warming and from the fact that cattle typically lose 6 % of ingested energy as methane. Several species of methanogens have been isolated from ruminants. However they are difficult to culture, few have been consistently found in high numbers, and it is likely that major species of rumen methanogens are yet to be identified.
        
        
          Results
          Total DNA from clarified bovine rumen fluid was amplified using primers specific for Archaeal 16S rRNA gene sequences (rDNA). Phylogenetic analysis of 41 rDNA sequences identified three clusters of methanogens. The largest cluster contained two distinct subclusters with rDNA sequences similar to Methanobrevibacter ruminantium 16S rDNA. A second cluster contained sequences related to 16S rDNA from Methanosphaera stadtmanae, an organism not previously described in the rumen. The third cluster contained rDNA sequences that may form a novel group of rumen methanogens.
        
        
          Conclusions
          The current set of 16S rRNA hybridization probes targeting methanogenic Archaea does not cover the phylogenetic diversity present in the rumen and possibly other gastro-intestinal tract environments. New probes and quantitative PCR assays are needed to determine the distribution of the newly identified methanogen clusters in rumen microbial communities.
Effects of long-term moderate exercise and increase in number of daily steps on serum lipids in women: randomised controlled trial [ISRCTN21921919]

Background
          This study was designed to evaluate the effects of a 24-month period of moderate exercise on serum lipids in menopausal women.
        
        
          Methods
          The subjects (40–60 y) were randomly divided into an exercise group (n = 14) and a control group (n = 13). The women in the exercise group were asked to participate in a 90-minute physical education class once a week and to record their daily steps as measured by a pedometer for 24 months.
        
        
          Results
          Mean of daily steps was significantly higher in the exercise group from about 6,800 to over 8,500 steps (P < 0.01). In the control group, the number of daily steps ranged from 5,700 to 6,800 steps throughout the follow-up period. A significant interaction between the exercise group and the control group in the changes og total cholesterol (TC), high-density lipoprotein cholesterol (HDLC) and TC : HDLC ratio could be observed (P < 0.05). By multiple regression analysis, the number of daily steps was related to HDLC and TC : HDLC levels after 24 months, and the changes in TC and HDLC concentrations.
        
        
          Conclusions
          These results suggest that daily exercise as well as increasing the number of daily steps can improve the profile of serum lipids.
Native interface of the SAM domain polymer of TEL

Background
          TEL is a transcriptional repressor containing a SAM domain that forms a helical polymer. In a number of hematologic malignancies, chromosomal translocations lead to aberrant fusions of TEL-SAM to a variety of other proteins, including many tyrosine kinases. TEL-SAM polymerization results in constitutive activation of the tyrosine kinase domains to which it becomes fused, leading to cell transformation. Thus, inhibitors of TEL-SAM self-association could abrogate transformation in these cells. In previous work, we determined the structure of a mutant TEL-SAM polymer bearing a Val to Glu substitution in center of the subunit interface. It remained unclear how much the mutation affected the architecture of the polymer, however.
        
        
          Results
          Here we determine the structure of the native polymer interface. To accomplish this goal, we introduced mutations that block polymer extension, producing a heterodimer with a wild-type interface. We find that the structure of the wild-type polymer interface is quite similar to the mutant structure determined previously. With the structure of the native interface, it is possible to evaluate the potential for developing therapeutic inhibitors of the interaction. We find that the interacting surfaces of the protein are relatively flat, containing no obvious pockets for the design of small molecule inhibitors.
        
        
          Conclusion
          Our results confirm the architecture of the TEL-SAM polymer proposed previously based on a mutant structure. The fact that the interface contains no obvious potential binding pockets suggests that it may be difficult to find small molecule inhibitors to treat malignancies in this way.